FDA

Kidneys
#Calliditas Therapeutics #FDA #Orphan drugs #Phase II trial

FDA orphan drug designation for Alport syndrome with setanaxib

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Calliditas Therapeutics for the treatment of Alport syndrome with setanaxib. Based on supportive pre-clinical work, Calliditas plans to initiate a randomised, placebo-controlled Phase II clinical study in Alport syndrome with around 20… Read More

#News

FDA
#Cancer research #FDA #Immunotherapy #Oncology #Orphan drugs

Orphan status granted to lymphoma maintenance therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 4SC’s resminostat (Kinselby) for cutaneous T-cell lymphoma (CTCL). Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. The company demonstrated that resminostat is… Read More

#News #Regulatory

#Antibody drug conjugate (ADC) #Cancer research #FDA #Mythic Therapeutics #Non-small cell lung cancer (NSCLC)

FDA fast-tracks ADC for non-small cell lung cancer 

The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression. The designation for Mythic, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for… Read More

#News

Blood cells
#Blood cancer #Bristol Myers Squibb #FDA #Oncology #Phase III trial

FDA expands Reblozyl approval to first-line use

The US Food and Drug Administration (FDA) has expanded the use of Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) to include first-line treatment of anaemia in adults with lower-risk myelodysplastic syndromes (MDS). The approval is for the treatment of anaemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low-… Read More

#News #Regulatory

Monoclonal antibody
#Alentis Therapeutics #Cancer research #FDA #Head and neck cancer #Monoclonal antibodies #Oncology

FDA fast-tracks monoclonal antibody for head and neck cancer

Fast Track designation from the Food and Drug Administration (FDA) will accelerate the path to US submission for Alentis Therapeutics’ investigational monoclonal antibody. ALE.C04 is indicated to treat patients with recurrent or metastatic CLDN1-positive head and neck squamous cell carcinoma (HNSCC). Fast Track designation aims to facilitate the development and… Read More

#Editor's Choice #News #Regulatory

#FDA #Immunology / Virology & Vaccines #Pfizer #Pregnancy #Respiratory syncytial virus

FDA approves RSV vaccine to protect babies from birth

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. Pfizer’s Abrysvo (Respiratory Syncytial Virus Vaccine) was approved for use at 32-36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD… Read More

#News #Regulatory

#FDA #Ipsen #Phase III trial #Rare disease #Regulatory

FDA approves first treatment for rare connective tissue disorder

Ipsen’s Sohonos (palovarotene) has become the first drug approved for patients with fibrodysplasia ossificans progressiva (FOP) in the US, following the granting of a marketing authorisation by the Food and Drug Administration (FDA). The capsules are approved for reduction in the volume of new heterotopic ossification (extra-skeletal bone formation) in… Read More

#News #Regulatory

Multiple myeloma
#Accelerated assessment #Bispecific Antibodies #FDA #Immunotherapy #Myeloma #Pfizer #Phase II trial

FDA accelerates approval for multiple myeloma immunotherapy

The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory… Read More

#News #Regulatory

Prostate cancer cells
#FDA #Gene mutation #Janssen #Oncology #Phase III trial #Prostate cancer

FDA approves dual action tablet for BRCA-positive prostate cancer

Janssen’s Akeega (niraparib and abiraterone acetate) is now available in the US for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) following FDA approval. It is the first dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, to be approved in… Read More

#News #Regulatory

EU and US flags
#Advanced Therapies #Cell and gene therapy #EMA #FDA #Regulatory

Overcoming diverging regulatory expectations to bring CGTs to market

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. Over the past few decades, the… Read More

#Exclusive Content #Regulatory #Trends & Analysis

FDA
#Bispecific Antibodies #FDA #Janssen #Myeloma #Oncology

Janssen myeloma drug approved in US via a restricted programme

The FDA has granted accelerated approval to Janssen’s talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma. It has been approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Talquetamab is a bispecific… Read More

#News #Regulatory

Test for AMD
#AMD #Astellas Pharma #FDA #Geographic atrophy #Ophthalmology

FDA approves Izervay for geographic atrophy

The US Food and Drug Administration (FDA) has approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The new complement C5 inhibitor is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at… Read More

#News #Regulatory

Patient speaking to psychiatrist
#FDA #Mental health #Postpartum depression #Sage Therapeutics

First oral drug for postpartum depression approved in US

The US Food and Drug Administration (FDA) has approved Sage Therapeutics’ Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. “Postpartum depression… Read More

#News #Regulatory

Endometrial cancer
#Cancer treatment #FDA #GSK #Oncology #Regulatory

FDA approves Jemperli plus chemo in endometrial cancer

GSK’s Jemperli (dostarlimab) has been approved in the US plus chemotherapy as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The US Food and Drug Administration (FDA) approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed… Read More

#News #Regulatory

Paediatric medicine concept
#Drug development #EMA #FDA #Paediatrics #Regulatory

What recent paediatric guidelines mean for drug developers 

Justin Hay, Senior Director, Amy Cheung Senior Director of Integrated Drug Development, and Patrick Loebs Director, at Certara, examine recent changes in paediatric guidelines and how they affect drug development projects.   It has been a very busy period recently for paediatric drug development with the release of many guidance documents… Read More

#Regulatory

FDA
#Acute Myeloid Leukaemia #Daiichi Sankyo #FDA #Haematology #Leukaemia

FDA approves quizartinib for acute myeloid leukaemia

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. It is approved with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following… Read More

#News #Regulatory